Jamjoom Pharmaceuticals Factory Company (4015.SR) stock analysis

In our weekly check, Jamjoom Pharmaceuticals Factory Company is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 4, red flags: 1.

About Jamjoom Pharmaceuticals Factory Company

Jamjoom Pharmaceuticals Factory Company is a Healthcare company (Drug Manufacturers - Specialty & Generic), listed on SAU as 4015.SR.

What our checks show for 4015.SR

Red flags

• Thinly traded (about 37 thousand shares a day): buying and selling can move the price.

Warning signs

• Analysts expect the net margin to shrink by 0.5 points from today's 30.5%.
• Free cash flow covers the dividend only 1 times.
• The stock has fallen as much as 44% from a peak. Would you have held through that?
• The stock is still below its previous peak.

Strengths

• Debt is low: 0.02x equity.
• Operating profit covers interest 108 times over.
• The net margin rose by 7.3 points over 5 years, to 30.5%.
• Analysts expect earnings per share to grow about 10.8% a year over the next years.
• Revenue grew 20% a year over the last 3 years.
• Earnings per share grew 41.7% a year over the last 3 years.

Similar companies

ALKS · AMRX · LNTH · ELAN · IPN.PA

Questions

What grade does Jamjoom Pharmaceuticals Factory Company (4015.SR) have?

In our weekly check, Jamjoom Pharmaceuticals Factory Company is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 4, red flags: 1. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 4015.SR stock?

This week's biggest flags for Jamjoom Pharmaceuticals Factory Company: Thinly traded, Margins expected to shrink, Dividend stretched. In total 5 of 25 checks show a warning or a red flag.

What does Jamjoom Pharmaceuticals Factory Company do?

Jamjoom Pharmaceuticals Factory Company is a Healthcare company (Drug Manufacturers - Specialty & Generic), listed on SAU as 4015.SR.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-07

Open the full analysis